Legal & General Group PLC Prometheus Biosciences, Inc. Transaction History

Legal & General Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $1.8 Million - $2.2 Million	17,407 Added 171.51%	27,556 $2.96 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $147,088 - $478,099	4,079 Added 67.2%	10,149 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $12,873 - $26,967	457 Added 8.14%	6,070 $358,000
Q2 2022 Aug 22, 2022	BUY	$22.39 - $38.94 $8,709 - $15,147	389 Added 7.45%	5,613 $158,000
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $26,303 - $43,650	-873 Reduced 14.32%	5,224 $197,000
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $114,652 - $203,472	5,146 Added 541.11%	6,097 $241,000
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $1,023 - $1,321	49 Added 5.43%	951 $23,000
Q2 2021 Aug 12, 2021	BUY	$16.8 - $29.65 $15,153 - $26,744	902 New	902 $22,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.